Research is being conducted on harnessing innate immune pathways for therapeutic advancement in cancer. Some studies are exploring the potential of targeting immunogenicity and immune evasion in cancer cells, while others are investigating specific strategies such as ALPK1 agonists and targeting CD24. The goal of this research appears to be the development of new cancer immunotherapies, with some studies focusing on specific types of cancer, such as cholangiocarcinoma and lymphoma.